Bifogade filer
Kurs & Likviditet
Prenumeration
Kalender
2025-02-20 | Bokslutskommuniké 2024 |
2024-11-21 | Kvartalsrapport 2024-Q3 |
2024-08-28 | Kvartalsrapport 2024-Q2 |
2024-05-16 | Ordinarie utdelning LIDDS 0.00 SEK |
2024-05-15 | Årsstämma 2024 |
2024-05-15 | Kvartalsrapport 2024-Q1 |
2024-02-27 | Extra Bolagsstämma 2024 |
2024-02-22 | Bokslutskommuniké 2023 |
2023-11-28 | Kvartalsrapport 2023-Q3 |
2023-08-30 | Kvartalsrapport 2023-Q2 |
2023-05-30 | Ordinarie utdelning LIDDS 0.00 SEK |
2023-05-29 | Kvartalsrapport 2023-Q1 |
2023-05-29 | Årsstämma 2023 |
2023-03-13 | Bokslutskommuniké 2022 |
2023-01-09 | Extra Bolagsstämma 2022 |
2022-11-28 | Kvartalsrapport 2022-Q3 |
2022-08-25 | Kvartalsrapport 2022-Q2 |
2022-06-02 | Ordinarie utdelning LIDDS 0.00 SEK |
2022-06-01 | Årsstämma 2022 |
2022-05-24 | Kvartalsrapport 2022-Q1 |
2022-02-23 | Bokslutskommuniké 2021 |
2021-11-22 | Kvartalsrapport 2021-Q3 |
2021-08-26 | Kvartalsrapport 2021-Q2 |
2021-05-18 | Kvartalsrapport 2021-Q1 |
2021-05-18 | Ordinarie utdelning LIDDS 0.00 SEK |
2021-05-17 | Årsstämma 2021 |
2021-02-25 | Bokslutskommuniké 2020 |
2020-11-19 | Kvartalsrapport 2020-Q3 |
2020-08-20 | Kvartalsrapport 2020-Q2 |
2020-05-15 | Ordinarie utdelning LIDDS 0.00 SEK |
2020-05-14 | Kvartalsrapport 2020-Q1 |
2020-05-14 | Årsstämma 2020 |
2020-02-27 | Bokslutskommuniké 2019 |
2019-11-28 | Kvartalsrapport 2019-Q3 |
2019-08-29 | Kvartalsrapport 2019-Q2 |
2019-05-17 | Ordinarie utdelning LIDDS 0.00 SEK |
2019-05-16 | Kvartalsrapport 2019-Q1 |
2019-05-16 | Årsstämma 2019 |
2019-02-28 | Bokslutskommuniké 2018 |
2018-11-29 | Kvartalsrapport 2018-Q3 |
2018-08-30 | Kvartalsrapport 2018-Q2 |
2018-05-17 | Ordinarie utdelning LIDDS 0.00 SEK |
2018-05-16 | Kvartalsrapport 2018-Q1 |
2018-05-16 | Årsstämma 2018 |
2018-02-22 | Bokslutskommuniké 2017 |
2017-11-09 | Kvartalsrapport 2017-Q3 |
2017-10-06 | Extra Bolagsstämma 2017 |
2017-08-31 | Kvartalsrapport 2017-Q2 |
2017-05-12 | Ordinarie utdelning LIDDS 0.00 SEK |
2017-05-11 | Årsstämma 2017 |
2017-05-11 | Kvartalsrapport 2017-Q1 |
2017-02-23 | Bokslutskommuniké 2016 |
2016-10-27 | Kvartalsrapport 2016-Q3 |
2016-08-24 | Kvartalsrapport 2016-Q2 |
2016-06-09 | Extra Bolagsstämma 2016 |
2016-04-22 | Årsstämma 2016 |
2016-04-22 | Kvartalsrapport 2016-Q1 |
2016-04-21 | Ordinarie utdelning LIDDS 0.00 SEK |
2016-02-10 | Bokslutskommuniké 2015 |
2015-10-29 | Kvartalsrapport 2015-Q3 |
2015-08-13 | Kvartalsrapport 2015-Q2 |
2015-04-22 | Ordinarie utdelning LIDDS 0.00 SEK |
2015-04-21 | Årsstämma 2015 |
2015-04-21 | Kvartalsrapport 2015-Q1 |
2015-02-20 | Bokslutskommuniké 2014 |
2014-11-11 | Kvartalsrapport 2014-Q3 |
2014-08-21 | Kvartalsrapport 2014-Q2 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
Due to technical issues, the date of Lidd's year-end report is being moved from March 10th to March 13th.
For additional information, please contact
Anders Månsson, CEO
Phone: +46 (0)70 860 47 38
E-mail: anders.mansson@liddspharma.com
LIDDS’ Certified Adviser is Redeye AB
LIDDS in brief:
LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.